Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor Phase 3 study in adults with non-cirrhotic NASH and F2-F3 fibrosis
NL-OMON56041Phase 3Recruiting
- Sponsor
- Inventiva
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Inventiva. Primary endpoint: Resolution of NASH and improvement of fibrosis at Week 72. Started Dec 2021; status: recruiting.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON56041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56041.